替拉珠单抗治疗中重度斑块状银屑病的安全性:三项随机对照试验的汇总分析
汇总三项随机对照试验(n=2081)评估替拉珠单抗治疗中重度斑块状银屑病长达64周的安全性。安慰剂对照期(至16周)内,替拉珠单抗100 mg、200 mg、安慰剂和依那西普组的不良事件频率相当;全试验期(至64周)暴露调整率显示替拉珠单抗组低于或相当于安慰剂组,且低于依那西普组。结论认为替拉珠单抗耐受性良好,严重不良事件、因不良事件停药及临床关注事件发生率低。
要点
- 安慰剂对照期内替拉珠单抗100 mg、200 mg、安慰剂和依那西普组治疗中出现的不良事件频率范围为47.9-54.0%,严重不良事件为1.4-2.3%。
- 全试验期内替拉珠单抗100 mg和200 mg的暴露调整不良事件率低于或相当于安慰剂组,且低于依那西普组。
- 未报告炎症性肠病或自杀的治疗中出现的不良事件;念珠菌皮肤感染和口腔念珠菌感染不常见。
核心结论
- 长达64周的替拉珠单抗治疗耐受性良好,严重治疗中出现的不良事件、因不良事件停药及临床关注的不良事件发生率低。
研究设计与样本
- 基于三项随机对照试验的汇总分析,纳入中重度斑块状银屑病患者(n=2081),分析安慰剂对照期(至16周)和全试验期(至64周)的数据。
主要发现
- 安慰剂对照期内,替拉珠单抗100 mg、替拉珠单抗200 mg、安慰剂和依那西普组的治疗中出现的不良事件频率范围为47.9-54.0%,严重治疗中出现的不良事件范围为1.4-2.3%,因不良事件停药范围为0.6-1.9%,主要不良心血管事件范围为0.0-0.1%,严重感染范围为0.0-0.3%,组间相当。
- 全试验期内,替拉珠单抗100 mg和200 mg的治疗中出现的不良事件、严重治疗中出现的不良事件和因不良事件停药的暴露调整率(每100患者年患者数)低于或相当于安慰剂组,且低于依那西普组。
- 全试验期内,主要不良心血管事件的暴露调整率范围为0.0-0.5,严重感染的暴露调整率范围为0.9-2.0,组间相当。
- 未报告炎症性肠病或自杀的治疗中出现的不良事件。
- 安慰剂对照期内,念珠菌皮肤感染在替拉珠单抗100 mg、替拉珠单抗200 mg、安慰剂和依那西普组的频率分别为0.1%、0.3%、0.0%和0.0%;全试验期内暴露调整率分别为0.2、0.7、0.0和0.0;口腔念珠菌感染也不常见。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Short-term interleukin-23p19 inhibition by tildrakizumab improves plaque psoriasis and appears to be well tolerated. OBJECTIVES: Safety and tolerability were assessed for up to 64 weeks of tildrakizumab therapy using pooled data from three randomized controlled trials for moderate-to-severe psoriasis. METHODS: Data pools for the placebo-controlled (up to 16 weeks) and full trial periods (up to 64 weeks) were analysed (n = 2081). RESULTS: In the placebo-controlled period, frequencies of treatment-emergent adverse events (TEAEs; range 47·9-54·0%), serious TEAEs (range 1·4-2·3%), discontinuations due to AEs (range 0·6-1·9%), major adverse cardiovascular events (MACEs; range 0·0-0·1%) and severe infections (range 0·0-0·3%) were comparable between tildrakizumab 100 mg, tildrakizumab 200 mg, placebo and etanercept. In the full trial period, exposure-adjusted rates (patients per 100 patient-years) for TEAEs, serious TEAEs and discontinuations due to AEs with tildrakizumab 100 mg and 200 mg were lower than or comparable with the placebo rates, and lower than with etanercept. Exposure-adjusted rates of MACEs (range 0·0-0·5) and severe infections (range 0·9-2·0) were comparable among groups. No TEAEs of inflammatory bowel disease or suicide were reported. Candida skin infections were infrequent at frequencies of 0·1%, 0·3%, 0·0% and 0·0% for the tildrakizumab 100 mg, tildrakizumab 200 mg, placebo and etanercept groups, respectively, in the placebo-controlled period, and exposure-adjusted rates of 0·2, 0·7, 0·0 and 0·0, respectively, in the full trial period. Oral candidiasis was also infrequent. CONCLUSIONS: Up to 64 weeks of tildrakizumab was well tolerated, with low rates of serious TEAEs, discontinuations due to AEs, and AEs of clinical interest.
引用
- Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018. PMID: 29742274. doi:10.1111/bjd.16724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。